Detalhe da pesquisa
1.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Blood
; 141(3): 219-230, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095849
2.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
3.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med
; 378(6): 518-528, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29231133
4.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(8): 754-66, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27557302
5.
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(12): 882-888, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716872
6.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 39(1): 81-89, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271807
7.
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 68-77, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357295
8.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
J Clin Oncol
; 41(6): 1265-1274, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658469
9.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20628153
10.
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Haematologica
; 97(12): 1925-8, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689676
11.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507715
12.
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
Cancer Rep (Hoboken)
; 5(11): e1603, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35168299
13.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): 690-701, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35764490
14.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Lancet Haematol
; 9(12): e897-e905, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215989
15.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Br J Haematol
; 153(2): 212-21, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21375521
16.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Eur J Haematol
; 86(1): 23-31, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20874823
17.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Eur J Haematol
; 86(5): 372-84, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21366694
18.
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(10): 701-710, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274290
19.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 37(10): 1779-1788, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34256668
20.
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica
; 100(5): e207-10, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25596270